Laila Schneidewind, Bernhard Kiss, Jennifer Kranz, Friedemann Zengerling, Angelika Borkowetz, Sebastian Graf, Annabel Graser, Annemarie Uhlig
{"title":"卡介苗注射治疗 NMIBC 后复发和病情发展的性别差异。","authors":"Laila Schneidewind, Bernhard Kiss, Jennifer Kranz, Friedemann Zengerling, Angelika Borkowetz, Sebastian Graf, Annabel Graser, Annemarie Uhlig","doi":"10.1159/000542473","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To assess gender-specific differences in recurrence-free (RFS), progression-free (PFS), cancer-specific survival (CSS) and overall survival (OS) among patients with intermediate or high-risk non-muscle invasive bladder cancer (NMIBC) receiving BCG is the primary aim of this systematic review and meta-analysis.</p><p><strong>Methods: </strong>In July 2023, we performed a literature search using MEDLINE, Embase and Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269). The detailed review protocol is accessible via CRD.</p><p><strong>Results: </strong>The systematic literature search identified 6,723 studies, of which 38 fulfilled the inclusion criteria. Random effect meta-analysis for RFS, based on data from 24 studies, revealed no statistically significant gender-specific difference (HR comparing males to females=0.9618, 95% CI: 0.8408-1.1003, p=0.5707). Similarly, for PFS, incorporating data from 14 studies, no statistically significant difference (HR =0.9540, 95% CI: 0.7709- 1.1805, p=0.6648), for CSS, analysis of data from three studies yielded no statistically significant difference (HR =0.9228, 95% CI: 0.6196-1.3743, p=0.6925), and for OS, based on data from two studies, no statistically significant difference was observed (HR = 1.1436, 95% CI: 0.5092-2.5684, p=0.7452). The risk of bias assessment indicated an overall moderate to high risk of bias.</p><p><strong>Conclusion: </strong>The findings indicate no association between gender and oncologic outcomes following BCG.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-17"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gender-specific differences in recurrence and progression following BCG instillation for NMIBC.\",\"authors\":\"Laila Schneidewind, Bernhard Kiss, Jennifer Kranz, Friedemann Zengerling, Angelika Borkowetz, Sebastian Graf, Annabel Graser, Annemarie Uhlig\",\"doi\":\"10.1159/000542473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>To assess gender-specific differences in recurrence-free (RFS), progression-free (PFS), cancer-specific survival (CSS) and overall survival (OS) among patients with intermediate or high-risk non-muscle invasive bladder cancer (NMIBC) receiving BCG is the primary aim of this systematic review and meta-analysis.</p><p><strong>Methods: </strong>In July 2023, we performed a literature search using MEDLINE, Embase and Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269). The detailed review protocol is accessible via CRD.</p><p><strong>Results: </strong>The systematic literature search identified 6,723 studies, of which 38 fulfilled the inclusion criteria. Random effect meta-analysis for RFS, based on data from 24 studies, revealed no statistically significant gender-specific difference (HR comparing males to females=0.9618, 95% CI: 0.8408-1.1003, p=0.5707). Similarly, for PFS, incorporating data from 14 studies, no statistically significant difference (HR =0.9540, 95% CI: 0.7709- 1.1805, p=0.6648), for CSS, analysis of data from three studies yielded no statistically significant difference (HR =0.9228, 95% CI: 0.6196-1.3743, p=0.6925), and for OS, based on data from two studies, no statistically significant difference was observed (HR = 1.1436, 95% CI: 0.5092-2.5684, p=0.7452). The risk of bias assessment indicated an overall moderate to high risk of bias.</p><p><strong>Conclusion: </strong>The findings indicate no association between gender and oncologic outcomes following BCG.</p>\",\"PeriodicalId\":23414,\"journal\":{\"name\":\"Urologia Internationalis\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologia Internationalis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000542473\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Gender-specific differences in recurrence and progression following BCG instillation for NMIBC.
Introduction: To assess gender-specific differences in recurrence-free (RFS), progression-free (PFS), cancer-specific survival (CSS) and overall survival (OS) among patients with intermediate or high-risk non-muscle invasive bladder cancer (NMIBC) receiving BCG is the primary aim of this systematic review and meta-analysis.
Methods: In July 2023, we performed a literature search using MEDLINE, Embase and Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269). The detailed review protocol is accessible via CRD.
Results: The systematic literature search identified 6,723 studies, of which 38 fulfilled the inclusion criteria. Random effect meta-analysis for RFS, based on data from 24 studies, revealed no statistically significant gender-specific difference (HR comparing males to females=0.9618, 95% CI: 0.8408-1.1003, p=0.5707). Similarly, for PFS, incorporating data from 14 studies, no statistically significant difference (HR =0.9540, 95% CI: 0.7709- 1.1805, p=0.6648), for CSS, analysis of data from three studies yielded no statistically significant difference (HR =0.9228, 95% CI: 0.6196-1.3743, p=0.6925), and for OS, based on data from two studies, no statistically significant difference was observed (HR = 1.1436, 95% CI: 0.5092-2.5684, p=0.7452). The risk of bias assessment indicated an overall moderate to high risk of bias.
Conclusion: The findings indicate no association between gender and oncologic outcomes following BCG.
期刊介绍：
Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
